394 related articles for article (PubMed ID: 30922100)
21. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.
Jha MK; Minhajuddin A; Gadad BS; Greer TL; Mayes TL; Trivedi MH
Brain Behav Immun; 2017 Nov; 66():103-110. PubMed ID: 28698115
[TBL] [Abstract][Full Text] [Related]
22. Early reduction in irritability is associated with improved outcomes among youth with depression: Findings from the AMOD study.
Mohamed AK; Croarkin PE; Jha MK; Vande Voort JL
J Affect Disord; 2023 Mar; 324():77-81. PubMed ID: 36549343
[TBL] [Abstract][Full Text] [Related]
23. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.
Rush AJ; Bernstein IH; Trivedi MH; Carmody TJ; Wisniewski S; Mundt JC; Shores-Wilson K; Biggs MM; Woo A; Nierenberg AA; Fava M
Biol Psychiatry; 2006 Mar; 59(6):493-501. PubMed ID: 16199008
[TBL] [Abstract][Full Text] [Related]
25. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Jha MK; Minhajuddin A; Gadad BS; Greer T; Grannemann B; Soyombo A; Mayes TL; Rush AJ; Trivedi MH
Psychoneuroendocrinology; 2017 Apr; 78():105-113. PubMed ID: 28187400
[TBL] [Abstract][Full Text] [Related]
26. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
27. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
[TBL] [Abstract][Full Text] [Related]
28. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
[TBL] [Abstract][Full Text] [Related]
29. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
30. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report.
Braund TA; Palmer DM; Williams LM; Harris AW
Aust N Z J Psychiatry; 2019 Aug; 53(8):782-793. PubMed ID: 30880405
[TBL] [Abstract][Full Text] [Related]
31. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Sung SC; Wisniewski SR; Luther JF; Trivedi MH; Rush AJ;
J Affect Disord; 2015 Mar; 174():157-64. PubMed ID: 25497473
[TBL] [Abstract][Full Text] [Related]
32. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Hall-Flavin DK; Winner JG; Allen JD; Carhart JM; Proctor B; Snyder KA; Drews MS; Eisterhold LL; Geske J; Mrazek DA
Pharmacogenet Genomics; 2013 Oct; 23(10):535-48. PubMed ID: 24018772
[TBL] [Abstract][Full Text] [Related]
33. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
[TBL] [Abstract][Full Text] [Related]
34. The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder.
Brown ES; Murray M; Carmody TJ; Kennard BD; Hughes CW; Khan DA; Rush AJ
Ann Allergy Asthma Immunol; 2008 May; 100(5):433-8. PubMed ID: 18517074
[TBL] [Abstract][Full Text] [Related]
35. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
36. Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial.
Madhoo M; Levine SZ
Eur Neuropsychopharmacol; 2016 Nov; 26(11):1768-1774. PubMed ID: 27707535
[TBL] [Abstract][Full Text] [Related]
37. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
Mohamed S; Johnson GR; Chen P; Hicks PB; Davis LL; Yoon J; Gleason TC; Vertrees JE; Weingart K; Tal I; Scrymgeour A; Lawrence DD; Planeta B; Thase ME; Huang GD; Zisook S; ; Rao SD; Pilkinton PD; Wilcox JA; Iranmanesh A; Sapra M; Jurjus G; Michalets JP; Aslam M; Beresford T; Anderson KD; Fernando R; Ramaswamy S; Kasckow J; Westermeyer J; Yoon G; D'Souza DC; Larson G; Anderson WG; Klatt M; Fareed A; Thompson SI; Carrera CJ; Williams SS; Juergens TM; Albers LJ; Nasdahl CS; Villarreal G; Winston JL; Nogues CA; Connolly KR; Tapp A; Jones KA; Khatkhate G; Marri S; Suppes T; LaMotte J; Hurley R; Mayeda AR; Niculescu AB; Fischer BA; Loreck DJ; Rosenlicht N; Lieske S; Finkel MS; Little JT
JAMA; 2017 Jul; 318(2):132-145. PubMed ID: 28697253
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
39. Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study.
Jha MK; Minhajuddin A; Chin Fatt C; Shoptaw S; Kircanski K; Stringaris A; Leibenluft E; Trivedi M
J Affect Disord; 2021 Sep; 292():108-113. PubMed ID: 34111690
[TBL] [Abstract][Full Text] [Related]
40. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
